ReviewNature reviews. Nephrology2011
The pathogenesis and diagnosis of acute kidney injury in multiple myeloma.
Review in Nature reviews. Nephrology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05429515 (Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury), which is not on this map. Cited by 105 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury: a Prospective Cohort Study
Who cites it
105 citing papers in PubMed, 2 syntheses or guidelines pooled it, 282 citations in OpenAlex.
- Light chains removal by extracorporeal techniques in acute kidney injury due to multiple myeloma: a position statement of the Onconephrology Work Group of the Italian Society of Nephrology.Journal of nephrology · 2016Guideline
- European Myeloma Network guidelines for the management of multiple myeloma-related complications.Haematologica · 2015Guideline
- Trial
- Multiple myeloma can be accurately diagnosed in acute kidney injury patients using a rapid serum free light chain test.BMC nephrology · 2017Trial
- Elevated red blood cell distribution width as a simple prognostic factor in patients with symptomatic multiple myeloma.BioMed research international · 2014Trial
- Postoperative acute kidney injury associated with cast nephropathy and marked renal interstitial plasma cell infiltration in multiple myeloma: a case report.CEN case reports · 2026Article
- Oridonin Protects Mice Against Cadmium-induced Kidney Injury by Inhibiting Ferroptosis via SIRT1 Regulation.Biological trace element research · 2026Article
- Extracorporeal Free-Light-Chain Removal in Myeloma Cast Nephropathy: Plasma Exchange and Hemodialysis Strategies in the Era of Effective Antimyeloma Therapy.Journal of clinical medicine · 2026Review
- A U-Shaped Association: The First-Year eGFR Slope and Mortality Risk in Multiple Myeloma.Cancer medicine · 2026Article
- A Multivariable Prediction Model for Early Mortality in Multiple Myeloma Patients With Renal Impairment.Cancer medicine · 2026Article
- Acute kidney injury with interstitial hemorrhage in renal heavy chain amyloidosis: a clinicopathologic case report.CEN case reports · 2026Article
- Cast nephropathy in the ICU: Early recognition and extracorporeal strategies to improve outcomes.Journal of intensive medicine · 2026Review
- Kidney function decline in working-age adults with cancer diagnosis: A study utilizing claims and health checkup data.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- A machine-learning-derived online prediction model based on inflammatory and nutritional composite indicators for acute kidney injury in sepsis patients with multiple myeloma.Frontiers in nutrition · 2026Article
- Parameters Associated With Renal Recovery and Survival in Myeloma Patients With Acute Renal Failure to Cast Nephropathy.American journal of hematology · 2026Article
- Application of individualized low-protein diet nursing for managing multiple myeloma patients with renal impairment.Medicine · 2025Observational
- Early daratumumab therapy improves renal outcomes in newly diagnosed patients with myeloma admitted with kidney injury.Blood advances · 2025Article
- Evaluation of Light Chain Removal Rates in Blood Purification Therapy for Light Chain Cast Nephropathy.Kidney medicine · 2025Article
- Global, regional, and national burden of multiple myeloma, 1990 to 2021 and predictions to 2035: an analysis of the Global Burden of Disease Study 2021.Frontiers in medicine · 2025Article
- A Novel Strategy for Assessing Bone Marrow Plasma Cell Percentage: Development and Internal Validation of a Surrogate Calculation Approach.Advances in hematology · 2025Article
45 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 9 institutions in 3 countries.
Funding
Abstract
Renal failure remains a principal cause of morbidity for patients with multiple myeloma. Once reversible factors such as hypercalcemia have been corrected, the most common cause of severe renal failure in these patients is a tubulointerstitial pathology that results from the very high circulating concentrations of monoclonal immunoglobulin free light chains. These endogenous proteins can result in isolated proximal tubule cell cytotoxicity, tubulointerstitial nephritis and cast nephropathy (myeloma kidney). Less frequently, high levels of free light chains can lead to immunoglobulin light chain amyloidosis and light chain deposition disease, although these conditions are usually associated with insidious progression of renal failure rather than acute kidney injury. Unless there is rapid intervention, progressive and irreversible damage occurs, particularly interstitial fibrosis and tubular atrophy. Despite advances in our understanding of the pathogenesis of these processes there has been a gap in translating these achievements into improved patient outcomes. The International Kidney and Monoclonal Gammopathy Research Group was formed to address this need. In this Review, we discuss the mechanisms of disease and diagnostic approaches to patients with acute kidney injury complicating multiple myeloma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.